Citations (114)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Nisha Yadav, Mohammad Saquib, Krishan Kumar Arya & Mohd Kamil Hussain. (2023) A Versatile New Approach to Bridgehead Nitrogen Bearing Benzimidazolo-Quinazoline Hybrids: Facile 1,4-Dipolar Cycloaddition of Benzyne and N-(1H-Benzo[d]Imidazol-2-yl)-1-Phenylmethanimines. Polycyclic Aromatic Compounds 43:6, pages 5582-5590.
Read now
Read now
Suchitra Nishal, Vikas Jhawat, Parmita Phaugat & Rohit Dutt. (2022) In vitro characterization of tofacitinib loaded novel nanoemulgel for topical delivery for the management of rheumatic arthritis. Drug Development and Industrial Pharmacy 48:8, pages 374-383.
Read now
Read now
Cecilia Dell’Avalle, Ferdinando D’Amico, Roberto Gabbiadini, Arianna Dal Buono, Nicola Pugliese, Alessandra Zilli, Federica Furfaro, Gionata Fiorino, Mariangela Allocca, Laurent Peyrin-Biroulet & Silvio Danese. (2022) JAK inhibitors in crohn’s disease: ready to go?. Expert Opinion on Investigational Drugs 31:2, pages 145-161.
Read now
Read now
Meng-Jie Wang, Yu-Hang Zhao, Chen Fan, Ying-Jie Wang, Xin-Qi Wang, Xiang-Jun Qiu & Rui-Le Shen. (2021) Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study. Drug Design, Development and Therapy 15, pages 4167-4175.
Read now
Read now
Celina Dubin, Ester Del Duca & Emma Guttman-Yassky. (2021) The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Review of Clinical Immunology 17:8, pages 835-852.
Read now
Read now
Erika L. Crowley, Novin Nezamololama, Kim Papp & Melinda J. Gooderham. (2020) Abrocitinib for the treatment of atopic dermatitis. Expert Review of Clinical Immunology 16:10, pages 955-962.
Read now
Read now
Qian Qiu, Qilin Feng, Xueying Tan & Mingxing Guo. (2019) JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. Expert Review of Clinical Pharmacology 12:6, pages 547-554.
Read now
Read now
Yoshiya Tanaka, Tatsuya Atsumi, Koichi Amano, Masayoshi Harigai, Taeko Ishii, Osamu Kawaguchi, Terence P. Rooney, Naotsugu Akashi & Tsutomu Takeuchi. (2018) Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. Modern Rheumatology 28:4, pages 583-591.
Read now
Read now
Ferdinando D’Amico, Gionata Fiorino, Federica Furfaro, Mariangela Allocca & Silvio Danese. (2018) Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opinion on Investigational Drugs 27:7, pages 595-599.
Read now
Read now
Daniel Wendling. (2016) An overview of investigational new drugs for treating ankylosing spondylitis. Expert Opinion on Investigational Drugs 25:1, pages 95-104.
Read now
Read now
Katherine A Steigerwald & Norman T Ilowite. (2015) Novel treatment options for juvenile idiopathic arthritis. Expert Review of Clinical Pharmacology 8:5, pages 559-573.
Read now
Read now
Articles from other publishers (103)
Shao-Liang Jiang, Wan-Jun Wang, Zhe-Ying Hu, Rong-Juan Zhang & Jie-Hua Shi. (2024) Comprehending the intermolecular interaction of JAK inhibitor fedratinib with bovine serum albumin (BSA)/human alpha-1-acid glycoprotein (HAG): Multispectral methodologies and molecular simulation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 304, pages 123277.
Crossref
Crossref
Sawsan Aboul-Fotouh, Ahmed Nageh Mahmoud, Esraa M. Elnahas, Mohamed Z. Habib & Sahar M. Abdelraouf. (2023) What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms. Virology Journal 20:1.
Crossref
Crossref
Hyunjung Park, Sangjik Lee, Jaehun Lee, Hyuk Moon & Simon Weonsang Ro. (2023) Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications. International Journal of Molecular Sciences 24:18, pages 13764.
Crossref
Crossref
Rioko Migita, Atsushi Tanaka, Kazuki Tanimoto, Junki Hiura, Yasutaka Kimoto, Takahiko Horiuchi & Yasushi Inoue. (2023) A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia. Modern Rheumatology Case Reports.
Crossref
Crossref
Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis
through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Crossref
Tatsuya Atsumi, Eri Asakura, Michio Doi, Ruta Sawant, Isao Kawaguchi, Nobuhito Sasaki & Danny Liew. (2023) Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. Modern Rheumatology 33:1, pages 54-63.
Crossref
Crossref
Kai Huang, Ying Ding, Linling Que, Nannan Chu, Yunfei Shi, Zhenzhong Qian, Wei Qin, Yuanxin Chen, Xianghong Gu, Jiakun Wang, Zhiwei Zhang, Jianguo Xu & Qing He. (2022) Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study. Frontiers in Pharmacology 13.
Crossref
Crossref
Zhengyu Fang, Yiping Hu, Jiajing Dai, Lianhua He, Juan He, Bihua Xu, Xinle Han, Fubo Zhong, Huiyao Lan & Qingwen Wang. (2022) CS12192, a Novel JAK3/JAK1/TBK1 Inhibitor, Synergistically Enhances the Anti-Inflammation Effect of Methotrexate in a Rat Model of Rheumatoid Arthritis. International Journal of Molecular Sciences 23:21, pages 13394.
Crossref
Crossref
Giuseppe Germanò, Pierluigi Macchioni, Beatrice Maranini, Giovanni Ciancio, Sara Bonazza, Marcello Govoni & Carlo Salvarani. (2022) Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study. Frontiers in Medicine 9.
Crossref
Crossref
Yifei Feng & Yan Lu. (2022) Advances in vitiligo: Update on therapeutic targets. Frontiers in Immunology 13.
Crossref
Crossref
Yu Zhuang, Qiushuang Sun, Tian Jing, Jia Liu, Haitao Meng, Yaqi Cao, Zhixia Qiu, Junen Sun & Ning Li. (2022) Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib. European Journal of Pharmaceutical Sciences 175, pages 106211.
Crossref
Crossref
Susmita Srivastava & Mahaboobkhan Rasool. (2022) Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis. Life Sciences 298, pages 120516.
Crossref
Crossref
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem & Ahmed M. Gouda. (2022) A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics 14:5, pages 1001.
Crossref
Crossref
Parnaz Daneshpajouhnejad, Jeffrey B. Kopp, Cheryl A. Winkler & Avi Z. Rosenberg. (2022) The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nature Reviews Nephrology 18:5, pages 307-320.
Crossref
Crossref
Suchitra Nishal, Vikas Jhawat, Parmita Phaugat & Rohit Dutt. (2022) Rheumatoid Arthritis and JAK-STAT Inhibitors: Prospects of Topical Delivery. Current Drug Therapy 17:2, pages 86-95.
Crossref
Crossref
Rioko Migita, Yasutaka Kimoto, Junki Hiura, Yuta Okumura & Takahiko Horiuchi. (2022) A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis. Case Reports in Rheumatology 2022, pages 1-5.
Crossref
Crossref
Elshaymaa Elmongy & Hanan Henidi. (2022) In Silico Evaluation of a Promising Key Intermediate Thieno [2,3-d] Pyrimidine Derivative with Expected JAK2 Kinase Inhibitory Activity. Molbank 2022:1, pages M1352.
Crossref
Crossref
Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K. Anderson & Mohamed‐Eslam F. Mohamed. (2021) Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials. Clinical and Translational Science 15:1, pages 267-278.
Crossref
Crossref
Xiaoyi Hu, Jing li, Maorong Fu, Xia Zhao & Wei Wang. (2021) The JAK/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Lu Zhang, Lian Wang & Xian Jiang. (2021)
The efficacy of
Janus
kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta‐analysis
. Dermatologic Therapy 34:5.
Crossref
Crossref
Ling ZhangYihang ZhangJihong Pan. (2021) Immunopathogenic mechanisms of rheumatoid arthritis and the use of anti-inflammatory drugs. Intractable & Rare Diseases Research 10:3, pages 154-164.
Crossref
Crossref
Paul Smith, Wenqing Yao, Stacey Shepard, Maryanne Covington, Jim Lee, Jennifer Lofland, Ahmad Naim, Trupti Sheth, Bhavnish Parikh & Swamy Yeleswaram. (2021) Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics 13:7, pages 1044.
Crossref
Crossref
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang & Shengyong Yang. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Klara Klein, Dagmar Stoiber, Veronika Sexl & Agnieszka Witalisz-Siepracka. (2021) Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?. Cancers 13:11, pages 2611.
Crossref
Crossref
Christopher J. Edwards, Ruta Sawant, Vishvas Garg, Ella X. Du, Alan Friedman & Keith A. Betts. (2020) A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy 8:1, pages 167-181.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Mukul Minocha, Sheryl Trueman, Tian Feng, Jeffrey Enejosa, Ogert Fisniku & Ahmed A. Othman. (2020) Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate. Clinical Pharmacology in Drug Development 10:3, pages 299-306.
Crossref
Crossref
Norito Katoh. (2020) Emerging treatments for atopic dermatitis. The Journal of Dermatology 48:2, pages 152-157.
Crossref
Crossref
Yuya Fujita, Naoki Matsuoka, Jumpei Temmoku, Makiko Furuya-Yashiro, Tomoyuki Asano, Shuzo Sato, Haruki Matsumoto, Hiroshi Watanabe, Hideko Kozuru, Hiroshi Yatsuhashi, Atsushi Kawakami & Kiyoshi Migita. (2020) JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. BMC Immunology 21:1.
Crossref
Crossref
Xia Zhao, Xiao Yan Sheng, Christopher D. Payne, Xin Zhang, Feng Wang & Yi Min Cui. (2020) Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study. Clinical Pharmacology in Drug Development 9:8, pages 952-960.
Crossref
Crossref
Biao Nie, Wanqing Wu, Yingjun Zhang, Huanfeng Jiang & Ji Zhang. (2020)
Recent advances in the synthesis of bridgehead (or ring-junction) nitrogen heterocycles
via
transition metal-catalyzed C–H bond activation and functionalization
. Organic Chemistry Frontiers 7:19, pages 3067-3099.
Crossref
Crossref
Janet Pope, Ruta Sawant, Namita Tundia, Ella X. Du, Cynthia Z. Qi, Yan Song, Patrick Tang & Keith A. Betts. (2020) Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Advances in Therapy 37:5, pages 2356-2372.
Crossref
Crossref
Miao Chen & Sheng-Ming Dai. (2020) A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chinese Medical Journal 133:8, pages 959-967.
Crossref
Crossref
Massimo Gadina, Danielle A. Chisolm, Rachael L. Philips, Iain B. McInness, Paul S. Changelian & John J. O’Shea. (2020) Translating JAKs to Jakinibs. The Journal of Immunology 204:8, pages 2011-2020.
Crossref
Crossref
Ahmed Nader, Sven Stodtmann, Anna Friedel, Mohamed‐Eslam F. Mohamed & Ahmed A. Othman. (2019) Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. The Journal of Clinical Pharmacology 60:4, pages 528-539.
Crossref
Crossref
Ahmed Nader, Mohamed‐Eslam F. Mohamed, Insa Winzenborg, Eva Doelger, Peter Noertersheuser, Aileen L. Pangan & Ahmed A. Othman. (2019) Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis. Clinical Pharmacology & Therapeutics 107:4, pages 994-1003.
Crossref
Crossref
Emma Guttman-Yassky, Diamant Thaçi, Aileen L. Pangan, H. Chih-ho Hong, Kim A. Papp, Kristian Reich, Lisa A. Beck, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Jaclyn K. Anderson, Yihua Gu, Henrique D. Teixeira & Jonathan I. Silverberg. (2020) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology 145:3, pages 877-884.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Denise Beck, Heidi S. Camp & Ahmed A. Othman. (2019) Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. The Journal of Clinical Pharmacology 60:2, pages 188-197.
Crossref
Crossref
Kyung Eun Kim, Suwon Jeon, Jisun Song, Tae Sung Kim, Min Kyung Jung, Myun Soo Kim, Sunyoung Park, Seung Beom Park, Jeong Min Park, Hyun Jeong Park & Daeho Cho. (2020) The Novel Synthetic Peptide AESIS-1 Exerts a Preventive Effect on Collagen-Induced Arthritis Mouse Model via STAT3 Suppression. International Journal of Molecular Sciences 21:2, pages 378.
Crossref
Crossref
Young Ho Lee & Gwan Gyu Song. (2019) Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 40:1, pages 65-72.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Tian Feng, Jeffrey V. Enejosa, Ogert Fisniku & Ahmed A. Othman. (2019) Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail. The Journal of Clinical Pharmacology 60:1, pages 86-95.
Crossref
Crossref
Georges El Hasbani, Ali Jawad & Imad Uthman. (2019) Update on the management of colchicine resistant Familial Mediterranean Fever (FMF). Orphanet Journal of Rare Diseases 14:1.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Ben Klünder, Heidi S. Camp & Ahmed A. Othman. (2019) Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection. Clinical Pharmacology & Therapeutics 106:6, pages 1319-1327.
Crossref
Crossref
H. Christian Eberl, Thilo Werner, Friedrich B. Reinhard, Stephanie Lehmann, Douglas Thomson, Peiling Chen, Cunyu Zhang, Christina Rau, Marcel Muelbaier, Gerard Drewes, David Drewry & Marcus Bantscheff. (2019) Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. Scientific Reports 9:1.
Crossref
Crossref
Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Kou Katayama, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Teruaki Shiomi, Emi Yamada & Désirée van der Heijde. (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid
arthritis and an inadequate response to methotrexate: results of a phase III
randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases 78:10, pages 1305-1319.
Crossref
Crossref
Sheryl Trueman, Mohamed‐Eslam F. Mohamed, Tian Feng, Ana Paula Lacerda, Thomas Marbury & Ahmed A. Othman. (2019) Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics. The Journal of Clinical Pharmacology 59:9, pages 1188-1194.
Crossref
Crossref
Romain Muller. (2019) JAK inhibitors in 2019, synthetic review in 10 points. European Journal of Internal Medicine 66, pages 9-17.
Crossref
Crossref
Ben Klünder, Rajendar K. Mittapalli, Mohamed-Eslam F. Mohamed, Anna Friedel, Peter Noertersheuser & Ahmed A. Othman. (2019) Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials. Clinical Pharmacokinetics 58:8, pages 1045-1058.
Crossref
Crossref
S.-C. Bae & Y. H. Lee. (2018) Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trialsVergleich der Wirksamkeit und Sicherheit von Tofacitinib und Baricitinib bei Patienten mit aktiver rheumatoider Arthritis: Bayes-Netz-Metaanalyse randomisierter kontrollierter Studien. Zeitschrift für Rheumatologie 78:6, pages 559-567.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Sheryl Trueman, Tian Feng, Jaclyn Anderson, Thomas C. Marbury & Ahmed A. Othman. (2019) Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics. The Journal of Clinical Pharmacology 59:6, pages 856-862.
Crossref
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2019) Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas. Medicina Clínica 152:9, pages 353-360.
Crossref
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2019) JAK-STAT inhibitors for the treatment of immunomediated diseases. Medicina Clínica (English Edition) 152:9, pages 353-360.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Sheryl Trueman, Tian Feng, Alan Friedman & Ahmed A. Othman. (2018) The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. The Journal of Clinical Pharmacology 59:4, pages 510-516.
Crossref
Crossref
Mohamed‐Eslam F. Mohamed, Jiewei Zeng, Patrick J. Marroum, In‐Ho Song & Ahmed A. Othman. (2018) Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials. Clinical Pharmacology in Drug Development 8:2, pages 208-216.
Crossref
Crossref
Mark Genovese, Rene Westhovens, Luc Meuleners, Annegret Van der Aa, Pille Harrison, Chantal Tasset & Arthur Kavanaugh. (2018) Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Research & Therapy 20:1.
Crossref
Crossref
Scott A. Scarneo, Antoine Mansourati, Liesl S. Eibschutz, Juliane Totzke, Jose R. Roques, David Loiselle, David Carlson, Philip Hughes & Timothy A. J. Haystead. (2018) Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific Reports 8:1.
Crossref
Crossref
Hisao Hamaguchi, Yasushi Amano, Ayako Moritomo, Shohei Shirakami, Yutaka Nakajima, Kazuo Nakai, Naoko Nomura, Misato Ito, Yasuyuki Higashi & Takayuki Inoue. (2018) Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorganic & Medicinal Chemistry 26:18, pages 4971-4983.
Crossref
Crossref
Elizabeth M. Dam, Alison C. Maier, Anne M. Hocking, Jeffrey Carlin, Bernard Ng & Jane H. Buckner. (2018) Increased Binding of Specificity Protein 1 to the IL21R Promoter in B Cells Results in Enhanced B Cell Responses in Rheumatoid Arthritis. Frontiers in Immunology 9.
Crossref
Crossref
Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence & John J O’Shea. (2018) Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology 104:3, pages 499-514.
Crossref
Crossref
Elena Peeva, Martin R. Hodge, Elizabeth Kieras, Michael L. Vazquez, Kosalaram Goteti, Sanela G. Tarabar, Christine W. Alvey & Christopher Banfield. (2018) Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. British Journal of Clinical Pharmacology 84:8, pages 1776-1788.
Crossref
Crossref
Ben Klünder, Mohamed-Eslam F. Mohamed & Ahmed A. Othman. (2017) Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials. Clinical Pharmacokinetics 57:8, pages 977-988.
Crossref
Crossref
Charles J. Malemud. (2018) The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 10:5-6, pages 117-127.
Crossref
Crossref
Chieyeon Chough, Misuk Joung, Sunmin Lee, Jaemin Lee, Jong Hoon Kim & B. Moon Kim. (2018) Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. Bioorganic & Medicinal Chemistry 26:8, pages 1495-1510.
Crossref
Crossref
Y. H. Lee & S.-C. Bae. (2017) Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritisVergleichende Wirksamkeit und Sicherheit von Baricitinib 2 mg und 4 mg bei Patienten mit aktiver rheumatoider Arthritis. Zeitschrift für Rheumatologie 77:4, pages 335-342.
Crossref
Crossref
Christopher Banfield, Matthew Scaramozza, Weidong Zhang, Elizabeth Kieras, Karen M. Page, Andrew Fensome, Michael Vincent, Martin E. Dowty, Kosalaram Goteti, Peter J. Winkle & Elena Peeva. (2017) The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology 58:4, pages 434-447.
Crossref
Crossref
Nicoletta Del Papa & Claudio Vitali. (2018) Management of primary Sjögren’s syndrome: recent developments and new classification criteria. Therapeutic Advances in Musculoskeletal Disease 10:2, pages 39-54.
Crossref
Crossref
Mark Carfagna, Ellen Cannady, Thomas Ryan, Jay Herman, Lew Truex, Kanchan Narwani & John Sullivan. (2018) Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats. Regulatory Toxicology and Pharmacology 92, pages 458-471.
Crossref
Crossref
Gang Fang, Qing Huai Zhang, Qianqian Tang, Zuling Jiang, Shasha Xing, Jianying Li & Yuzhou Pang. (2017) Comprehensive analysis of gene expression and DNA methylation datasets identify valuable biomarkers for rheumatoid arthritis progression. Oncotarget 9:3, pages 2977-2983.
Crossref
Crossref
Chieyeon Chough, Sunmin Lee, Misuk Joung, Jaemin Lee, Jong Hoon Kim & B. Moon Kim. (2018)
Design, synthesis and evaluation of (
R
)-3-(7-(methyl(7
H
-pyrrolo[2,3-
d
]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor
. MedChemComm 9:3, pages 477-489.
Crossref
Crossref
Ting-Shun Wang & Tsen-Fang Tsai. (2017) Tofacitinib in psoriatic arthritis. Immunotherapy 9:14, pages 1153-1163.
Crossref
Crossref
Ian Todd, Ola H. Negm, Jenna Reps, Paul Radford, Grazziela Figueredo, Elizabeth M. McDermott, Elizabeth Drewe, Richard J. Powell, Susan Bainbridge, Mohamed Hamed, Sharon Crouch, Jon Garibaldi, Steve St-Gallay, Lucy C. Fairclough & Patrick J. Tighe. (2017) A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing. Pharmacological Research 125, pages 188-200.
Crossref
Crossref
Mohamed-Eslam F. Mohamed, Steven Jungerwirth, Armen Asatryan, Ping Jiang & Ahmed A. Othman. (2017) Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. British Journal of Clinical Pharmacology 83:10, pages 2242-2248.
Crossref
Crossref
Frédéric Vanhoutte, Minodora Mazur, Oleksandr Voloshyn, Mykola Stanislavchuk, Annegret Van der Aa, Florence Namour, René Galien, Luc Meuleners & Gerben van 't Klooster. (2017) Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis & Rheumatology 69:10, pages 1949-1959.
Crossref
Crossref
John HynesJr.Jr., Hong Wu, James Kempson, James J.-W. Duan, Zhonghui Lu, Bin Jiang, Sylwia Stachura, John S. Tokarski, John S. Sack, Javed A. Khan, Jonathan S. Lippy, Rosemary F. Zhang, Sidney Pitt, Guoxiang Shen, Kate Gillooly, Kim McIntyre, Percy H. Carter, Joel C. Barrish, Steven G. Nadler, Luisa M. Salter-Cid, Aberra Fura, Gary L. Schieven, William J. Pitts & Stephen T. Wrobleski. (2017) Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors. Bioorganic & Medicinal Chemistry Letters 27:14, pages 3101-3106.
Crossref
Crossref
A Kavanaugh, J Kremer, L Ponce, R Cseuz, O V Reshetko, M Stanislavchuk, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset & P Harrison. (2017) Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Annals of the Rheumatic Diseases 76:6, pages 1009-1019.
Crossref
Crossref
R Westhovens, P C Taylor, R Alten, D Pavlova, F Enríquez-Sosa, M Mazur, M Greenwald, A Van der Aa, F Vanhoutte, C Tasset & P Harrison. (2017) Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Annals of the Rheumatic Diseases 76:6, pages 998-1008.
Crossref
Crossref
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni & Daniella M. Schwartz. (2017) JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:5, pages 521-546.
Crossref
Crossref
Santos Castañeda & Isidoro González-Álvaro. (2017) Innovations in the therapeutic outlook of rheumatoid arthritis. Reumatología Clínica (English Edition) 13:2, pages 63-65.
Crossref
Crossref
Santos Castañeda & Isidoro González-Álvaro. (2017) Novedades en el panorama terapéutico de la artritis reumatoide. Reumatología Clínica 13:2, pages 63-65.
Crossref
Crossref
Jurgen Heymann, Cheryl A Winkler, Maarten Hoek, Katalin Susztak & Jeffrey B Kopp. (2017) Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. Nephrology Dialysis Transplantation 32:suppl_1, pages i65-i70.
Crossref
Crossref
Mohamed-Eslam F. Mohamed, Heidi S. Camp, Ping Jiang, Robert J. Padley, Armen Asatryan & Ahmed A. Othman. (2016) Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clinical Pharmacokinetics 55:12, pages 1547-1558.
Crossref
Crossref
Joel M. Kremer, Paul Emery, Heidi S. Camp, Alan Friedman, Li Wang, Ahmed A. Othman, Nasser Khan, Aileen L. Pangan, Steven Jungerwirth & Edward C. Keystone. (2016) A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis & Rheumatology 68:12, pages 2867-2877.
Crossref
Crossref
Róbert Kiss, Dávid Bajusz, Rebekah Baskin, Katalin Tóth, Katalin Monostory, Peter P. Sayeski & György M. Keserű. (2016) Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells. Archiv der Pharmazie 349:12, pages 925-933.
Crossref
Crossref
Dávid Bajusz, György G. Ferenczy & György M. Keserű. (2016) Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. Journal of Molecular Graphics and Modelling 70, pages 275-283.
Crossref
Crossref
Ying Jun Cao, Taiji Sawamoto, Udaya Valluri, Kathy Cho, Michaelene Lewand, Suzanne Swan, Kenneth Lasseter, Mark Matson, John HolmanJrJr, James Keirns & Tong Zhu. (2016) Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects. Clinical Pharmacology in Drug Development 5:6, pages 435-449.
Crossref
Crossref
Peng Wang, Jin-Hui Tao & Hai-Feng Pan. (2016) Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis. Inflammopharmacology 24:5, pages 189-196.
Crossref
Crossref
Joachim. R. Kalden. (2016) Emerging Therapies for Rheumatoid Arthritis. Rheumatology and Therapy 3:1, pages 31-42.
Crossref
Crossref
Jiaojiao Xu, Jin Cai, Junqing Chen, Xi Zong, Xuan Wu, Min Ji & Peng Wang. (2019) An Efficient Synthesis of Baricitinib. Journal of Chemical Research 40:4, pages 205-208.
Crossref
Crossref
Ilaria Pagnini, Federico Bertini & Rolando Cimaz. (2016) Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options. Pediatric Drugs 18:2, pages 101-108.
Crossref
Crossref
Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai, Takehiro Aoki, Douglas Schlichting, Terence Rooney & William Macias. (2016) Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. The Journal of Rheumatology 43:3, pages 504-511.
Crossref
Crossref
Fiona?J. Sorrell, Marta Szklarz, Kamal?R. Abdul?Azeez, Jon?M. Elkins & Stefan Knapp. (2016) Family-wide Structural Analysis of Human Numb-Associated Protein Kinases. Structure 24:3, pages 401-411.
Crossref
Crossref
M Buchert, C J Burns & M Ernst. (2015) Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35:8, pages 939-951.
Crossref
Crossref
Steffanie L. Furtek, Donald S. Backos, Christopher J. Matheson & Philip Reigan. (2016) Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chemical Biology 11:2, pages 308-318.
Crossref
Crossref
J Vier, M Groth, M Sochalska & S Kirschnek. (2016) The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death & Disease 7:2, pages e2103-e2103.
Crossref
Crossref
Uddalak Bharadwaj, Moses M. Kasembeli & David J. Tweardy. 2016. STAT Inhibitors in Cancer. STAT Inhibitors in Cancer
95
161
.
Marc D. Cohen & Edward C. Keystone. (2015) JAK Inhibitors for Rheumatoid Arthritis. Current Treatment Options in Rheumatology 1:4, pages 305-319.
Crossref
Crossref
John D. Isaacs. (2015) 10 years of therapeutic advances in the rheumatic diseases. Nature Reviews Rheumatology 11:11, pages 628-630.
Crossref
Crossref
Pawel Gunerka, Barbara Dymek, Aleksandra Stanczak, Anna Bujak, Paulina Grygielewicz, Pawel Turowski, Karolina Dzwonek, Monika Lamparska-Przybysz, Tadeusz Pietrucha & Maciej Wieczorek. (2015) Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors. European Journal of Pharmacology 765, pages 188-197.
Crossref
Crossref
Li Tan, Koshi Akahane, Randall McNally, Kathleen M. S. E. ReyskensScott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. PattisonKatherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. ArthurMichael J. Eck & Nathanael S. Gray. (2015) Development of Selective Covalent Janus Kinase 3 Inhibitors. Journal of Medicinal Chemistry 58:16, pages 6589-6606.
Crossref
Crossref
R F van Vollenhoven, M Layton, L Kahl, L Schifano, E Hachulla, D Machado, D Staumont-Sallé & J Patel. (2015) DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus 24:6, pages 648-649.
Crossref
Crossref
Ingo Muegge, Delphine Collin, Brian Cook, Melissa Hill-Drzewi, Josh Horan, Stanley Kugler, Mark Labadia, Xiang Li, Lana Smith & Yunlong Zhang. (2015) Discovery of 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide analogs as new RORC modulators. Bioorganic & Medicinal Chemistry Letters 25:9, pages 1892-1895.
Crossref
Crossref
Nancy Labastida-Mercado, Samantha Galindo-Becerra, Javier Garcés-Eisele, Perla Colunga-Pedraza, Valeria Guzman-Olvera, Virginia Reyes-Nuñez, Guillermo J. Ruiz-Delgado & Guillermo J. Ruiz-Argüelles. (2015) The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Hematology/Oncology and Stem Cell Therapy 8:1, pages 16-21.
Crossref
Crossref
Christel J Menet, Oscar Mammoliti & Miriam López-Ramos. (2015) Progress toward JAK1-selective inhibitors. Future Medicinal Chemistry 7:2, pages 203-235.
Crossref
Crossref
C. Bohórquez, A. Turrión, A. Movasat & M. Álvarez Mon. (2014) Actualización en el tratamiento de la artritis reumatoide. Medicine - Programa de Formación Médica Continuada Acreditado 11:69, pages 4112-4121.
Crossref
Crossref